Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial | |
Im, Seock-Ah; Xu, Binghe; Li, Wei; Robson, Mark; Ouyang, Quchang; Yeh, Dah-Cherng; Iwata, Hiroji; Park, Yeon-Hee; Sohn, Joo Hyuk; Tseng, Ling-Min | |
2018 | |
卷号 | 78期号:4 |
ISSN号 | 0008-5472 |
URL标识 | 查看原文 |
收录类别 | SCIE |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6360475 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Im, Seock-Ah,Xu, Binghe,Li, Wei,et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial[J],2018,78(4). |
APA | Im, Seock-Ah.,Xu, Binghe.,Li, Wei.,Robson, Mark.,Ouyang, Quchang.,...&Masuda, Norikazu.(2018).Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial.,78(4). |
MLA | Im, Seock-Ah,et al."Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial".78.4(2018). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论